The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
May 16th 2025
Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.
Pfizer and Lilly Preparing to Resume Phase 3 Chronic Pain Program for Tanezumab
March 23rd 2015This announcement follows the FDA's decision to lift the partial clinical hold on the tanezumab development program. after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab
Read More
Bayer Furthers Global Efforts to Lead Fight Against Vector-Borne Diseases
March 23rd 2015In its 10th year, the Companion Vector-Borne Diseases (CVBD®) World Forum leads a global public health conversation on vector-borne diseases under the banner: "One Health: joining efforts for a healthier world".
Read More